MiNK Therapeutics is a clinical stage biopharmaceutical company engaged in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Co.'s key product candidate, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy. In addition, Co. is developing a pipeline of allogeneic iNKT programs. Co.'s key programs include a CAR-iNKT program targeting B-cell maturation antigen (BCMA), which it refers to as BCMA-CAR-iNKT, and a tumor stromal targeting CAR-iNKT program, which it refers to as stromal target-CAR-iNKT. These programs are both in preclinical development. The INKT average annual return since 2021 is shown above.
The Average Annual Return on the INKT average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether INKT average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the INKT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|